We are live on ! Find out more
AYTU icon

AYTU BioPharma
AYTU

39 hedge funds and large institutions have $12.2M invested in AYTU BioPharma in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 11

0.26% less ownership

Funds ownership: 1.03% → 0.77% (-0.26%)

22% less funds holding

Funds holding: 50 → 39 (-11)

26% less call options, than puts

Call options by funds: $194K | Put options by funds: $261K

53% less capital invested

Capital invested by funds: $26.1M → $12.2M (-$13.9M)

79% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 14

Holders
39
Holders Change
-11
Holders Change %
-22%
% of All Funds
0.68%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
17
Reduced
11
Closed
14
Calls
$194K
Puts
$261K
Net Calls
-$67K
Net Calls Change
-$633K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$1.26M
2
Renaissance Technologies
Renaissance Technologies
New York
+$688K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$366K
4
Citadel Advisors
Citadel Advisors
Florida
+$237K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$200K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$6.72M
2
VF
Virtu Financial
New York
-$510K
3
E
Ergoteles
New York
-$378K
4
TEE
Tibra Equities Europe
United Kingdom
-$301K
5
Millennium Management
Millennium Management
New York
-$301K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$19K -$66.9K -891 -73%
Wells Fargo
27
Wells Fargo
California
$9K -$525 -7 -4%
UBS Group
28
UBS Group
Switzerland
$5K +$2.48K +33 +72%
TRCT
29
Tower Research Capital (TRC)
New York
$4K -$34.7K -462 -86%
CA
30
Clearstead Advisors
Ohio
$4K – – –
Simplex Trading
31
Simplex Trading
Illinois
$3K – – –
SCA
32
Stonebridge Capital Advisors
Minnesota
$2K -$2.85K -38 -50%
IA
33
IFP Advisors
Florida
$2K +$1.5K +20 +200%
Federated Hermes
34
Federated Hermes
Pennsylvania
$2K +$2.48K +33 New
Royal Bank of Canada
35
Royal Bank of Canada
Ontario, Canada
$1K -$19.4K -259 -90%
FWM
36
Focused Wealth Management
New York
$1K – – –
AC
37
Armistice Capital
New York
– -$6.72M -67,119 Closed
VF
38
Virtu Financial
New York
– -$510K -5,090 Closed
E
39
Ergoteles
New York
– -$378K -3,774 Closed
TEE
40
Tibra Equities Europe
United Kingdom
– -$301K -3,005 Closed
Squarepoint
41
Squarepoint
New York
– -$173K -1,724 Closed
PCM
42
Pinz Capital Management
New York
– -$107K -1,070 Closed
Deutsche Bank
43
Deutsche Bank
Germany
– -$104K -1,040 Closed
Jane Street
44
Jane Street
New York
– -$78K -786 Closed
Citigroup
45
Citigroup
New York
– -$3K -40 Closed
GWM
46
Geneos Wealth Management
Colorado
– -$3K -39 Closed
KFS
47
Kelly Financial Services
Massachusetts
– -$122K -31 Closed
BAM
48
Bellevue Asset Management
Washington
– -$1K -13 Closed
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
– -$1K -10 Closed
Fidelity Investments
50
Fidelity Investments
Massachusetts
– +$375 +5 New
1
2

AYTU Hedge Fund Activity: Q3 2021 in Review

39 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q3 2021, worth a combined $12.2M — down 53% from $26.1M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of AYTU and 3 opened new positions — a net loss of 11 holders — while 11 trimmed existing stakes and 17 added.

The largest buyer was Morgan Stanley, adding an estimated $1.26M. The largest seller was Armistice Capital, exiting entirely with an estimated $6.72M sold.

  • 39 institutional investors held AYTU BioPharma (AYTU) as of Q3 2021, down from 50 in Q2 2021.
  • Funds reported $12.2M of AYTU BioPharma stock for Q3 2021, down 53% quarter-over-quarter.
  • 3 funds opened new AYTU BioPharma positions in Q3 2021 and 14 closed out, a net change of -11 holders.
  • The largest AYTU BioPharma buyer in Q3 2021 was Morgan Stanley, an estimated $1.26M added.
  • The largest AYTU BioPharma seller in Q3 2021 was Armistice Capital, an estimated $6.72M sold.

Based on aggregated 13F filings for Q3 2021.